Amarin Celebrates New Guidelines Including CV Risk Treatment for Hypertriglyceridemia Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2026
0mins
Amarin celebrated the recommendation that the treatment of CV risk in patients with hypertriglyceridemia be part of a broader dyslipidemia management as discussed in the 2026 American College of Cardiology, or ACC, / American Heart Association, or AHA,/Multisociety Dyslipidemia Guideline Update. These newly-issued, evidenced-based recommendations summarize the clinical role of icosapent ethyl in reducing cardiovascular, or CV, risk in statin-treated patients with elevated triglycerides, or TG, and fully align with Amarin's commitment to addressing the burden of CV disease across the healthcare ecosystem. The updated guideline reinforces that patients on statin therapy can experience residual CV risk driven by elevated TG levels - a significant clinical challenge affecting millions of Americans. Amarin's VASCEPA/VAZKEPA, or icosapent ethyl, is an effective, safe, oral therapy that has been prescribed more than 30M times globally.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMRN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMRN
About AMRN
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Supreme Court Rules in Favor of Hikma Pharmaceuticals
- Patent Litigation Concluded: The U.S. Supreme Court ruled in favor of Hikma Pharmaceuticals and its subsidiary, effectively ending Amarin's patent infringement litigation, marking a significant victory for Hikma in the legal dispute over its generic icosapent ethyl medication, ensuring continued access to affordable medicines.
- Accelerated Market Access: Hikma's icosapent ethyl received FDA approval and launched a generic version of Amarin's branded product Vascepa in 2020, utilizing a 'skinny label' strategy aimed at expediting patient access to lower-cost medications, thereby enhancing market penetration.
- Legal Challenge Response: Despite Amarin's allegations of improper marketing of its generic drug, a U.S. district court dismissed the suit, and a federal appeals court later revived it; the Supreme Court's ruling ultimately provided clear support for Hikma's legal standing and business practices.
- Positive Stock Reaction: HIK.L closed at 1,460p on Thursday, up 44p or 3.11%, reflecting the market's positive response to the Supreme Court ruling and bolstering confidence in Hikma's future growth prospects.
See More
Supreme Court Backs Hikma's 'Skinny Labels' Ruling Against Amarin
- Legal Impact: The Supreme Court's unanimous ruling supports Hikma against Amarin, affirming the legality of 'skinny labels' which allows Hikma's generic Vascepa to omit cardiovascular event reduction indications, thus avoiding patent litigation and enhancing competitiveness in the generic drug market.
- Positive Market Reaction: Following the ruling, shares of Liquidia surged, indicating increased market confidence in generic manufacturers, which may encourage more companies to adopt 'skinny label' strategies, further driving industry growth.
- Amarin's Response: Amarin expressed disappointment over the ruling and is evaluating next steps, yet remains committed to ensuring its innovative drug VASCEPA reaches patients, demonstrating resilience in the face of competitive challenges.
- Industry Outlook: This ruling could provide advantages for other generic drugmakers, especially when facing legal challenges from brand manufacturers, suggesting that the generic drug market may see more opportunities in the future.
See More
Amarin Unveils New Cardiovascular Disease Identification Method at EAS Congress
- New Identification Method: Amarin Corporation presented post hoc analysis data from the REDUCE-IT trial at the 2026 European Atherosclerosis Society Congress, proposing a new method for identifying cardiovascular disease using risk-weighted apolipoprotein B levels, which could change screening standards for cardiovascular diseases.
- Cardiovascular Disease Statistics: Cardiovascular disease is the leading cause of death globally, accounting for 915,973 deaths annually in the U.S. alone, with high low-density lipoprotein cholesterol (LDL-C) increasing the risk of cardiovascular events by 35%, underscoring the importance of effective LDL-C management.
- REDUCE-IT Trial Findings: Conducted over seven years, the REDUCE-IT trial evaluated the efficacy of VASCEPA (icosapent ethyl), showing that the drug effectively lowers LDL-C levels and reduces cardiovascular disease risk, enrolling a total of 8,179 patients with hypertriglyceridemia.
- Future Treatment Recommendations: Based on the REDUCE-IT results, Amarin updated its recommendations in 2025 for high doses of icosapent ethyl for very high-risk cardiovascular disease patients, further solidifying the drug's significance in cardiovascular disease management.
See More
Amarin Q1 Earnings Report Analysis
- Earnings Performance: Amarin reported a Q1 GAAP EPS of -$0.03, missing expectations by $0.04, indicating ongoing profitability challenges that could negatively impact investor confidence.
- Revenue Growth: The company achieved revenues of $45.1 million, a 7.3% year-over-year increase, beating market expectations by $1.33 million, suggesting robust product demand that may lay the groundwork for future growth.
- Cash Position: As of March 31, 2026, Amarin's total cash and investments rose to $307.8 million from $302.6 million as of December 31, 2025, reflecting improvements in the company's cash management.
- Operating Loss Reduction: The operating loss narrowed from $16.8 million to $11.3 million, an improvement of $5.4 million or 32%, which included $3.3 million in restructuring costs, indicating progress in cost control efforts.
See More
Amarin Expected to Exceed Q1 Earnings Estimates
- Earnings Announcement Date: Amarin (AMRN) is set to release its Q1 2025 earnings on April 29 before market open, with a consensus EPS estimate of $0.17, a significant improvement from -$0.02 in Q1 2025, indicating strong potential for profitability.
- Revenue Growth Expectations: The revenue estimate for Q1 stands at $43.77 million, reflecting a 4.2% year-over-year increase, suggesting that the company is enhancing its sales capabilities in the market, which may lay the groundwork for future growth.
- Historical Performance: Over the past two years, Amarin has beaten EPS estimates 100% of the time and revenue estimates 63% of the time, this consistent performance boosts investor confidence and could lead to a stock price increase.
- Market Reaction Anticipation: Given Amarin's strong track record, the market is generally optimistic about the upcoming earnings report, which is expected to further enhance the company's competitiveness in the biopharmaceutical sector.
See More
Amarin Faces Challenges, Restructures for Survival
- Strong Financial Position: Amarin carries no long-term debt, with a cash balance of nearly $135 million and short-term investments just under $168 million, indicating a robust financial position that can sustain operations for years.
- Declining Sales Revenue: Despite generating nearly $183 million in product sales for Vascepa in 2025, this represents a significant decline from $285 million two years ago, primarily due to generic competition in the U.S. market, forcing the company to cut spending to maintain financial health.
- Restructuring Efforts: The restructuring implemented in 2025 aims to reduce costs, with management believing it will lead to positive free cash flow in 2026, although the market challenges remain severe.
- Competitive Market Pressures: With only one drug to sell and facing intense market competition, Amarin's risk of business contraction increases, potentially leading to unfavorable outcomes for shareholders, prompting investors to favor larger pharmaceutical companies with broader drug portfolios.
See More
U.S. Supreme Court Rules in Favor of Hikma Pharmaceuticals
- Patent Litigation Concluded: The U.S. Supreme Court ruled in favor of Hikma Pharmaceuticals and its subsidiary, effectively ending Amarin's patent infringement litigation, marking a significant victory for Hikma in the legal dispute over its generic icosapent ethyl medication, ensuring continued access to affordable medicines.
- Accelerated Market Access: Hikma's icosapent ethyl received FDA approval and launched a generic version of Amarin's branded product Vascepa in 2020, utilizing a 'skinny label' strategy aimed at expediting patient access to lower-cost medications, thereby enhancing market penetration.
- Legal Challenge Response: Despite Amarin's allegations of improper marketing of its generic drug, a U.S. district court dismissed the suit, and a federal appeals court later revived it; the Supreme Court's ruling ultimately provided clear support for Hikma's legal standing and business practices.
- Positive Stock Reaction: HIK.L closed at 1,460p on Thursday, up 44p or 3.11%, reflecting the market's positive response to the Supreme Court ruling and bolstering confidence in Hikma's future growth prospects.
See More
Supreme Court Backs Hikma's 'Skinny Labels' Ruling Against Amarin
- Legal Impact: The Supreme Court's unanimous ruling supports Hikma against Amarin, affirming the legality of 'skinny labels' which allows Hikma's generic Vascepa to omit cardiovascular event reduction indications, thus avoiding patent litigation and enhancing competitiveness in the generic drug market.
- Positive Market Reaction: Following the ruling, shares of Liquidia surged, indicating increased market confidence in generic manufacturers, which may encourage more companies to adopt 'skinny label' strategies, further driving industry growth.
- Amarin's Response: Amarin expressed disappointment over the ruling and is evaluating next steps, yet remains committed to ensuring its innovative drug VASCEPA reaches patients, demonstrating resilience in the face of competitive challenges.
- Industry Outlook: This ruling could provide advantages for other generic drugmakers, especially when facing legal challenges from brand manufacturers, suggesting that the generic drug market may see more opportunities in the future.
See More
Amarin Unveils New Cardiovascular Disease Identification Method at EAS Congress
- New Identification Method: Amarin Corporation presented post hoc analysis data from the REDUCE-IT trial at the 2026 European Atherosclerosis Society Congress, proposing a new method for identifying cardiovascular disease using risk-weighted apolipoprotein B levels, which could change screening standards for cardiovascular diseases.
- Cardiovascular Disease Statistics: Cardiovascular disease is the leading cause of death globally, accounting for 915,973 deaths annually in the U.S. alone, with high low-density lipoprotein cholesterol (LDL-C) increasing the risk of cardiovascular events by 35%, underscoring the importance of effective LDL-C management.
- REDUCE-IT Trial Findings: Conducted over seven years, the REDUCE-IT trial evaluated the efficacy of VASCEPA (icosapent ethyl), showing that the drug effectively lowers LDL-C levels and reduces cardiovascular disease risk, enrolling a total of 8,179 patients with hypertriglyceridemia.
- Future Treatment Recommendations: Based on the REDUCE-IT results, Amarin updated its recommendations in 2025 for high doses of icosapent ethyl for very high-risk cardiovascular disease patients, further solidifying the drug's significance in cardiovascular disease management.
See More
Amarin Q1 Earnings Report Analysis
- Earnings Performance: Amarin reported a Q1 GAAP EPS of -$0.03, missing expectations by $0.04, indicating ongoing profitability challenges that could negatively impact investor confidence.
- Revenue Growth: The company achieved revenues of $45.1 million, a 7.3% year-over-year increase, beating market expectations by $1.33 million, suggesting robust product demand that may lay the groundwork for future growth.
- Cash Position: As of March 31, 2026, Amarin's total cash and investments rose to $307.8 million from $302.6 million as of December 31, 2025, reflecting improvements in the company's cash management.
- Operating Loss Reduction: The operating loss narrowed from $16.8 million to $11.3 million, an improvement of $5.4 million or 32%, which included $3.3 million in restructuring costs, indicating progress in cost control efforts.
See More
Amarin Expected to Exceed Q1 Earnings Estimates
- Earnings Announcement Date: Amarin (AMRN) is set to release its Q1 2025 earnings on April 29 before market open, with a consensus EPS estimate of $0.17, a significant improvement from -$0.02 in Q1 2025, indicating strong potential for profitability.
- Revenue Growth Expectations: The revenue estimate for Q1 stands at $43.77 million, reflecting a 4.2% year-over-year increase, suggesting that the company is enhancing its sales capabilities in the market, which may lay the groundwork for future growth.
- Historical Performance: Over the past two years, Amarin has beaten EPS estimates 100% of the time and revenue estimates 63% of the time, this consistent performance boosts investor confidence and could lead to a stock price increase.
- Market Reaction Anticipation: Given Amarin's strong track record, the market is generally optimistic about the upcoming earnings report, which is expected to further enhance the company's competitiveness in the biopharmaceutical sector.
See More
Amarin Faces Challenges, Restructures for Survival
- Strong Financial Position: Amarin carries no long-term debt, with a cash balance of nearly $135 million and short-term investments just under $168 million, indicating a robust financial position that can sustain operations for years.
- Declining Sales Revenue: Despite generating nearly $183 million in product sales for Vascepa in 2025, this represents a significant decline from $285 million two years ago, primarily due to generic competition in the U.S. market, forcing the company to cut spending to maintain financial health.
- Restructuring Efforts: The restructuring implemented in 2025 aims to reduce costs, with management believing it will lead to positive free cash flow in 2026, although the market challenges remain severe.
- Competitive Market Pressures: With only one drug to sell and facing intense market competition, Amarin's risk of business contraction increases, potentially leading to unfavorable outcomes for shareholders, prompting investors to favor larger pharmaceutical companies with broader drug portfolios.
See More
